Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;3(6):519-26.
doi: 10.1093/ndtplus/sfq164. Epub 2010 Sep 21.

Individualizing anaemia therapy

Angel L M de Francisco  1
Affiliations

Individualizing anaemia therapy

Angel L M de Francisco. NDT Plus. 2010 Dec.

Abstract

Individualized strategies for managing renal anaemia with erythropoiesis-stimulating agents (ESAs) need to be advanced. Recent outcomes from clinical studies prompted a narrowing of the guideline-recommended haemoglobin target (11-12 g/dL) due to increased mortality and morbidity when targeting higher haemoglobin concentrations. Maintaining a narrow target is a clinical challenge, as haemoglobin concentration tends to fluctuate. The goal of individualized treatment is to achieve the haemoglobin target at the lowest ESA dose while avoiding significant fluctuations in haemoglobin concentrations and persistently low or high concentrations. This may require changes to the ESA dose and dosing frequency over the course of treatment.

Keywords: anaemia; erythropoiesis-stimulating agents; haemoglobin.

PubMed Disclaimer

References

    1. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:33–38. - PMC - PubMed
    1. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis. 2004;44:94–111. - PubMed
    1. Boudville NC, Djurdjev O, Macdougall IC, et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol. 2009;4:1176–1182. - PMC - PubMed
    1. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15–24. - PubMed
    1. Cody J, Daly C, Campbell M, et al. Cochrane Database Syst Rev. 2005. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. CD003266. - PubMed

LinkOut - more resources